CA3113414A1 - Protocole psychedelique pour systemes et methodes informatiques - Google Patents
Protocole psychedelique pour systemes et methodes informatiquesInfo
- Publication number
- CA3113414A1 CA3113414A1 CA3113414A CA3113414A CA3113414A1 CA 3113414 A1 CA3113414 A1 CA 3113414A1 CA 3113414 A CA3113414 A CA 3113414A CA 3113414 A CA3113414 A CA 3113414A CA 3113414 A1 CA3113414 A1 CA 3113414A1
- Authority
- CA
- Canada
- Prior art keywords
- protocol
- client
- psychedelics
- processor
- integration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001337 psychedelic effect Effects 0.000 title claims abstract description 76
- 239000003196 psychodysleptic agent Substances 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims abstract description 25
- 230000010354 integration Effects 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims description 47
- 230000004044 response Effects 0.000 claims description 18
- 238000004891 communication Methods 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 description 49
- 238000012806 monitoring device Methods 0.000 description 8
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 7
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 7
- 230000036651 mood Effects 0.000 description 5
- 238000005352 clarification Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Developmental Disabilities (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Social Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Bioethics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3113414A CA3113414A1 (fr) | 2021-03-29 | 2021-03-29 | Protocole psychedelique pour systemes et methodes informatiques |
| PCT/CA2022/050471 WO2022204805A1 (fr) | 2021-03-29 | 2022-03-29 | Systèmes et procédés informatiques de protocole de traitement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3113414A CA3113414A1 (fr) | 2021-03-29 | 2021-03-29 | Protocole psychedelique pour systemes et methodes informatiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3113414A1 true CA3113414A1 (fr) | 2022-09-29 |
Family
ID=83439932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3113414A Pending CA3113414A1 (fr) | 2021-03-29 | 2021-03-29 | Protocole psychedelique pour systemes et methodes informatiques |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA3113414A1 (fr) |
| WO (1) | WO2022204805A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240203553A1 (en) * | 2022-12-19 | 2024-06-20 | Andria Orlowski | Opioid treatment system & method |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163090A1 (fr) * | 2012-04-23 | 2013-10-31 | Sackett Solutions & Innovations, LLC | Systèmes de biométrie cognitive destinés à mesurer les émotions et le stress |
| RU2700983C2 (ru) * | 2013-10-25 | 2019-09-24 | Арес Трейдинг С.А. | Система наблюдения за пациентом, сообщающая соблюдение схемы лечения |
| RU2722748C2 (ru) * | 2015-01-10 | 2020-06-03 | Дебора ДУЛЛЕН | Устройство и способ измерения вегетативных функций для диагностики и подтверждения эффективности курса лечения пациента и его результатов |
| US11798689B2 (en) * | 2016-07-25 | 2023-10-24 | Viecure, Inc. | Generating customizable personal healthcare treatment plans |
| CA3079560A1 (fr) * | 2017-10-19 | 2019-04-25 | Eleusis Benefit Corporation, Pbc | Procedes et systemes d'amelioration de la securite des pharmacotherapies psychedeliques |
| WO2019246239A1 (fr) * | 2018-06-19 | 2019-12-26 | Ellipsis Health, Inc. | Systèmes et procédés d'évaluation de santé mentale |
| US20220071958A1 (en) * | 2019-02-22 | 2022-03-10 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
| WO2020181194A1 (fr) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions et méthodes d'utilisation comprenant des substances ayant des actions de plasticité neurale administrées à des doses et formulations non psychédéliques/psychotomimétiques |
| WO2020198065A1 (fr) * | 2019-03-22 | 2020-10-01 | Cognoa, Inc. | Procédés et dispositifs de thérapie numérique personnalisée |
| US10559386B1 (en) * | 2019-04-02 | 2020-02-11 | Kpn Innovations, Llc | Methods and systems for an artificial intelligence support network for vibrant constituional guidance |
| CN113993522A (zh) * | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法 |
-
2021
- 2021-03-29 CA CA3113414A patent/CA3113414A1/fr active Pending
-
2022
- 2022-03-29 WO PCT/CA2022/050471 patent/WO2022204805A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022204805A1 (fr) | 2022-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cardoso-Leite et al. | A new look at sensory attenuation: Action-effect anticipation affects sensitivity, not response bias | |
| JP7487872B2 (ja) | 医療システム及びそれを実行する方法 | |
| US10827926B2 (en) | Systems and methods for assessing cognitive function | |
| Perry et al. | Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients | |
| Moore et al. | The interruptive effect of pain on attention | |
| US20150170542A1 (en) | Comprehensive management of human health | |
| Loring et al. | A brief behavioral intervention for insomnia in adolescents with autism spectrum disorders. | |
| Gazarian et al. | A description of nurses' decision‐making in managing electrocardiographic monitor alarms | |
| Zdanowicz et al. | Insomnia, sleepiness, and fatigue among polish nurses | |
| Carter et al. | Autonomous and controlled motivation for eating disorders treatment: Baseline predictors and relationship to treatment outcome | |
| Brunet et al. | Validation of sleep-2-Peak: A smartphone application that can detect fatigue-related changes in reaction times during sleep deprivation | |
| Milkins et al. | The potential benefits of targeted attentional bias modification on cognitive arousal and sleep quality in worry-related sleep disturbance | |
| US12053300B2 (en) | System and method for instituting wellness practices | |
| Riley | Patient fatigue during aphasia treatment: A survey of speech-language pathologists | |
| JP7391443B1 (ja) | 医療・療法システムを統合するデータベース及びそれを実行する方法 | |
| Reichenbach et al. | Human performance consequences of automated decision aids in states of sleep loss | |
| JP2023155465A (ja) | 医療・療法システムを統合するデータベース及びそれを実行する方法 | |
| Valeriani et al. | Correlation between abnormal brain excitability and emotional symptomatology in paediatric migraine | |
| Greenlee et al. | Modality changes in vigilance displays: further evidence of supramodal resource depletion in vigilance | |
| Fowers et al. | Using mobile meditation app data to predict future app engagement: an observational study | |
| Irish | Deciphering the physician—older patient interaction | |
| CA3113414A1 (fr) | Protocole psychedelique pour systemes et methodes informatiques | |
| Charles et al. | Feeling free: External influences on endogenous behaviour | |
| Samora et al. | Applications of immersive virtual reality for illicit substance use: A systematic review | |
| Bault et al. | Dissociation between private and social counterfactual value signals following ventromedial prefrontal cortex damage |